(NASDAQ: FBLG) Fibrobiologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.18%.
Fibrobiologics's earnings in 2026 is -$18,680,000.On average, 6 Wall Street analysts forecast FBLG's earnings for 2026 to be -$10,174,574, with the lowest FBLG earnings forecast at -$14,497,452, and the highest FBLG earnings forecast at -$5,414,667. On average, 6 Wall Street analysts forecast FBLG's earnings for 2027 to be -$5,419,355, with the lowest FBLG earnings forecast at -$7,555,010, and the highest FBLG earnings forecast at -$3,062,842.
In 2028, FBLG is forecast to generate -$4,622,391 in earnings, with the lowest earnings forecast at -$5,921,495 and the highest earnings forecast at -$3,172,229.